S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

PVLA Palvella Therapeutics Inc

16.88

0.73 (4.52%)

13 Feb 2025 - Closed

Delayed by 15 minutes

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Palvella Therapeutics (NASDAQ:PVLA)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Palvella Therapeutics Charts.

Palvella Therapeutics (NASDAQ:PVLA)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Palvella Therapeutics Charts.

Palvella Therapeutics Inc News

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
Tuesday 11 February 2025 (2 days ago) • Edgar (US Regulatory)

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
Tuesday 11 February 2025 (3 days ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 8 February 2025 (5 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 8 February 2025 (5 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 8 February 2025 (5 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 8 February 2025 (5 days ago) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Saturday 18 January 2025 (4 weeks ago) • Edgar (US Regulatory)

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
Saturday 11 January 2025 (1 month ago) • GlobeNewswire Inc.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Thursday 9 January 2025 (1 month ago) • Edgar (US Regulatory)

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
Thursday 9 January 2025 (1 month ago) • GlobeNewswire Inc.

Form 3/A - Initial statement of beneficial ownership of securities: [Amend]
Tuesday 7 January 2025 (1 month ago) • Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933
Tuesday 31 December 2024 (1 month ago) • Edgar (US Regulatory)

More Palvella Therapeutics Inc News Articles

Australian SE All Ordina...

Westpac Banking

AUD vs US Dollar

Invesco QQQ Trust Series 1

Australia And New Zealan...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions